# Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)

Source: https://onco.cc/trials/nct02953301/  
OnCo record `nct02953301` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Resminostat in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by 4SC AG, completed.

## Summary

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) is a phase 2 interventional study registered as NCT02953301 by 4SC AG, with 201 participants recorded, started 2016-11 and reaching its primary completion in 2023-03. Interventions recorded: resminostat, Placebo. Conditions recorded: Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous.

Linked to the drug Resminostat because the registry names it among its interventions and Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02953301
- Phase: 2
- Setting: A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study
- Sponsor: 4SC AG
- Enrolled: 201

## Sources

- ClinicalTrials.gov NCT02953301: https://clinicaltrials.gov/study/NCT02953301

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Resminostat](https://onco.cc/drugs/resminostat/)
- companies: [4SC](https://onco.cc/companies/4sc/)

---
JSON: https://onco.cc/api/v1/entities/nct02953301.json